Voyageur Engages Fluor for Iodine and Contrast Drug Feasibility Studies

Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) has taken a significant step toward securing North America's medical imaging drug supply chain by engaging Fluor Corporation, a global engineering leader, to conduct comprehensive feasibility studies. The studies cover two strategic projects: an iodine extraction facility in Oklahoma, USA, developed in collaboration with Bayer AG using Voyageur's patent-pending Mueller process, and an integrated barium and iodine contrast drug manufacturing plant. The iodine project aims to produce high-purity iodine from oilfield brine for contrast media, while the manufacturing facility will combine domestically sourced iodine with barium from Voyageur's 100%-owned Frances Creek deposit, creating the first fully integrated "Earth-to-Bottle" contrast media platform in North America.

The feasibility studies, budgeted at US$2,350,000 for the Bayer project, are expected to be completed in early 2027, paving the way for a potential construction decision later that year. Fluor's expertise in process engineering and project economics ensures the studies meet high technical and environmental standards required for financing and regulatory approvals. Voyageur CEO Brent Willis emphasized the partnership's role in de-risking and accelerating the projects, stating, "We are moving decisively toward securing North America’s supply chain for critical medical imaging drugs." The dual studies build on Voyageur's progress, including Health Canada-approved barium contrast products already generating commercial sales, and the ongoing Bayer collaboration, which may advance to an offtake-linked production financing arrangement.

Voyageur is positioned as a low-cost, vertically integrated producer of barium and iodine Active Pharmaceutical Ingredients (APIs) and finished contrast agents. By owning the Frances Creek barite project and leveraging the Mueller process for iodine extraction, the company controls its raw material supply. Its proprietary Streamline manufacturing technology enables end-to-end production from raw materials to finished drugs, reducing costs and creating a reliable North American supply chain. This strategy, embodied in the motto "From Earth to Bottle," addresses geopolitical and shortage risks for hospitals and patients in the U.S. and Canada. For further information, visit https://voyageurpharmaceuticals.ca.